Seeking Alpha

FDA approves supplemental patient cohort for HeartWare's Endurance trial

  • The FDA approves and IDE supplement allowing HeartWare International (HTWR -0.6%) to enroll an additional patient cohort for the Endurance destination therapy study.
  • Data from the new cohort will be included in a PMA application seeking a destination therapy indication for the HeartWare System. (PR)
  • More on the Endurance trial: Northland sees "glaring inconsistencies."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: